WO2007132207A2 - Process for cross-linking moieties - Google Patents
Process for cross-linking moieties Download PDFInfo
- Publication number
- WO2007132207A2 WO2007132207A2 PCT/GB2007/001745 GB2007001745W WO2007132207A2 WO 2007132207 A2 WO2007132207 A2 WO 2007132207A2 GB 2007001745 W GB2007001745 W GB 2007001745W WO 2007132207 A2 WO2007132207 A2 WO 2007132207A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- moiety
- linker
- conjugate
- alkyl
- enzyme
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 92
- 238000004132 cross linking Methods 0.000 title abstract description 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 7
- 239000000872 buffer Substances 0.000 claims description 32
- 229910006127 SO3X Inorganic materials 0.000 claims description 26
- 229940088598 enzyme Drugs 0.000 claims description 22
- 239000011324 bead Substances 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 229920002521 macromolecule Polymers 0.000 claims description 11
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 230000001268 conjugating effect Effects 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- -1 C^-Cw-alkyl Inorganic materials 0.000 claims description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 230000035484 reaction time Effects 0.000 claims description 7
- 229910006069 SO3H Inorganic materials 0.000 claims description 6
- 150000005829 chemical entities Chemical class 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108010015776 Glucose oxidase Proteins 0.000 claims description 4
- 239000004366 Glucose oxidase Substances 0.000 claims description 4
- 150000004985 diamines Chemical class 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 229940116332 glucose oxidase Drugs 0.000 claims description 4
- 235000019420 glucose oxidase Nutrition 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 description 39
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical group OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 13
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000021615 conjugation Effects 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 7
- 229910021538 borax Inorganic materials 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 235000010339 sodium tetraborate Nutrition 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical group [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 0 *c(**1*)c(*)c(N=C=S)c1O* Chemical compound *c(**1*)c(*)c(N=C=S)c1O* 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 240000003291 Armoracia rusticana Species 0.000 description 4
- 235000011330 Armoracia rusticana Nutrition 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000893 inhibin Substances 0.000 description 4
- 108010067471 inhibin A Proteins 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UPNUQQDXHCUWSG-UHFFFAOYSA-N 1-[6-(4-azido-2-nitroanilino)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O UPNUQQDXHCUWSG-UHFFFAOYSA-N 0.000 description 1
- MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102000037829 Anion channels Human genes 0.000 description 1
- 108091006515 Anion channels Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229910021474 group 7 element Inorganic materials 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/30—Isothiocyanates containing at least two isothiocyanate groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
Definitions
- the invention relates to a linkers for linking moieties such as nucleic acids, proteins, antibodies and polypeptides with other moieties such as enzymes, antibodies and solid supports, and processes using such linkers.
- Crosslinking reagents are often used in the diagnostic, pharmaceutical, chemical, electronic and biotechnology industries to produce conjugates such as DNA and antibodies with enzymes, and proteins with biotin. These conjugates ' find applications as nucleic acid probes and in immunoassays, amongst others. Crosslinking reactions are also used in the immobilisation of macromolecules on solid supports such as glass, microprocessors, membranes, dipsticks and magnetic beads.
- crosslinking reagents and methods are known in the prior art.
- Pierce market a kit for controlled protein-protein crosslinking which depends on the reaction of a thiol with a maleiimide group (Perbio Science UK 05/06, Pierce 23456) and disuccinimidyl suberate, a homobifunctional agent (Pierce 21655).
- Other reagents include the photoactivatable sulfo-SANPAH (sulfosuccinimidyl 6-(4'-aizido-2'-nitro- phenylamino)hexanoate) .
- a key disadvantage of the methods mentioned above is that the thiol/maleiimide approach is an all-day procedure requiring several complicated steps using unstable reagents.
- the thiols readily oxidise and dimerise, and the maleiimides can hydrolyse.
- the homobifunctional reagents suffer from self-conjugation and polymerisation. Additionally, rapid hydrolysis leading to poor yields and the required use of high concentrations of such toxic reagents are also disadvantages, Photoactivatable reagents also show poor discrimination and are often low yielding.
- the invention therefore provides linkers which are suitable for linking a first moiety with a second moiety and processes using such linkers.
- the invention also provides "activated" first moieties which comprise first moieties conjugated to linkers of the invention in a form in which they can be used for conjugation to a second moiety, and processes for the production of such "activated” moieties.
- the invention therefore provides a process for linking a first moiety with a linker, wherein the first moiety comprises one or more free amino groups and wherein the first moiety is not a cell membrane or cell membrane fraction, the process comprising the steps: ,
- R 1 to R 4 , R 7 to R 10 ' R 11 to R 14 and R 17 to R 20 are independently selected from H 3 halogen, Ci-io-alky ⁇ , Cs-s-cycloalkyl, OH, O-Ci- 3 -alkyl, SH, NH 2 , NO 2 , CO 2 H, SO 3 H and SO 3 X 3 wherein X denotes a counter ion, for example, NH 4 + , Na + or K + ;
- R 5 , R 6 , R 15 and R 16 are independently selected from H 3 halogen, Ci- ⁇ -alkyl, OH 3 O-Ci-3-alkyl, SH 3 NH 23 CO 2 H 3 and CO 2 -C i- 3 -alkyl 3
- n and n are independently I 3 2 or 3
- Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone.
- the invention further relates to a process for conjugating a first moiety with a second moiety, wherein the first and second moieties independently comprise one or more free amino groups, the process comprising the steps:
- R 1 to R 4 , R 7 to R 10 , R 11 to R 14 and R 17 to R 20 are independently selected from
- R 5 3 R 6 3 R 15 and R 16 are independently selected from H 3 halogen, Ct-e-alkyl,
- n and n are independently I 3 2 or 3
- Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone
- step (i) is carried out under the conditions:
- step (ii) is carried out under the conditions:
- each pair of R 5 and R 6 groups may, independently of any other R 5 and R 6 pairs, be either in the cis or in the trans geometrical isomeric configuration; and wherein each R 5 may be the same or different, and wherein each R 6 may be the same or different.
- R 15 and R 16 and m are the same or different.
- Ci-io-alkyl denotes a branched or unbranched alkyl group having between 1 and 10 carbon atoms.
- the group includes methyl, ethyl, n-propyl, w ⁇ -propyl, w-butyl, x ' so-butyl, sec-butyl, tert-butyl etc.
- C3-s-cycloalkyl denotes a cyclic alkyl group having between 3 and 8 carbon atoms in the ring.
- the group includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- O-Ch-3-alkyl denotes an alkoxy group having between 1 and 3 carbon atoms in the alkyl portion.
- the group includes methoxy, ethoxy, n- propoxy and w ⁇ -propoxy.
- CO2-Ci-3-alkyl denotes an ester group having between 1 and 3 carbqn atoms in the alkyl portion.
- the group includes methyl carboxylate, ethyl carboxylate, r ⁇ -propyl carboxylate and w ⁇ -propyl carboxylate.
- halogen denotes an atom of a group VII element selected from among fluorine, chlorine, bromine and iodine.
- free amino group (s) refers to amino groups which are capable of reacting with the isothiocyanate groups of the linker.
- free amino groups include those present in the amino acids lysine, arginine, asparagine and glutamine of polypeptides or at the N terminus of polypeptides.
- R 1 to R 4 , R 7 to R 10 , R 11 to R 14 and R 17 to R 20 are each independently selected from H, methyl, ethyl and SO3X.
- R 5 , R 6 , R 15 and R 16 are each independently selected from H and Ci-3 alkyl.
- R 1 to R 4 and R 7 to R 10 are SO3X. Particularly preferably, only one of R 1 to R 4 and/or only one of R 7 to R 10 are SO3X. Most preferably, only one of R 1 to R 4 and/or only one of R 7 to R 10 are SO 3 X wherein R 4 is SO 3 X and/or R 7 is SO 3 X.
- R 11 to R 14 and R 17 to R 20 are SO 3 X. Particularly preferably, only one of R 11 to R 14 and/or only one of R 17 to R 20 are SO 3 X. Most preferably, only one of R 11 to R 14 and/or only one of R 17 to R 20 are SO 3 X wherein R 14 is SO 3 X and/or R 17 is SO 3 X.
- X is preferably Na + .
- the linker is a compound of formula III:
- R groups, X, m and n are as defined above.
- R 1 to R 20 are preferably independently selected from H, methyl and ethyl. Most preferably, R 1 to R 20 , when present, are all H.
- a particularly preferred linker is 4,4'-diisothiocyanato-2,2'-stilbenedisulfonic acid (DIDS, Aldrich 28,561-7).
- the corresponding dimerised linker i.e. the compound of formula IV, wherein R 1 to R 3 , R 5 , R 6 , R 8 to R 10 , R n to R 13 , R 15 , R 16 and R 18 to R 20 are all H, and n and m are both 1) is also particularly preferred.
- the organic linker Y is preferably a linear C2-6-alkyl, most preferably C2-4- alkyl group, optionally substituted at one or more of the backbone carbon atoms by one or more groups selected from halogen, Ci-3-alkyl, O-Ci-3-alkyl, CO 2 H and CO 2 -Ci- 3 -alkyl.
- Y is -CH2CH2-.
- Y is -(CHa) 4 CH(COOH)-.
- the dimerised linkers are selected from the compounds of general formulae IX and X:
- the first and second moieties which may be the same or different, are preferably a chemical entity and/or a solid support.
- the chemical entity is an isolated or purified Chemical entity.
- chemical entities include macromolecules, most preferably biological macromolecules.
- biological macromolecules include nucleic acid molecules, proteins, polypeptides and peptides.
- the biological macromolecule is in isolated or purified form, e.g. an isolated nucleic acid molecule or a purified protein, polypeptide or peptide.
- nucleic acid molecules include DNA and RNA.
- the nucleic acid molecule may be single-stranded or double-stranded or part single- and part double- stranded.
- the macromolecule is a single-stranded oligomer, preferably a DNA oligomer.
- proteins and polypeptides include enzymes and antibodies.
- the enzyme is an enzyme which is capable of -producing a detectable reaction, such as horseradish peroxidase, alkaline phosphatase, beta galactosidase, glucose oxidase or a restriction enzyme.
- the first and/or second moiety is not a cell membrane or a cell membrane fraction.
- cell membrane or cell membrane fraction is meant that the first and/or second moiety is not a biological cell membrane (e.g. a membrane from a red blood cell) or a fraction therefore, for example a fraction that has been obtained by centrifugation of the cell membrane in a solvent.
- the first and/or second moiety is not a cell membrane protein, in particular not an anion channel protein.
- the first and/or second moieties may also be a structural binding peptide such as streptavidin or avidin, or a label, such as biotin.
- one or both of the moieties may be an antibody.
- the antibodies may be of any suitable source, e.g. monoclonal, polyclonal, chimeric, bispecific, single-chain or fragments thereof.
- Antibody fragments include, but are not limited to. Fab, Fab' and F(ab')2, Fd, single- chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain.
- Antigen-binding antibody fragments may comprise the variable region (s) alone or in combination with the entirety or a portion of the following: hinge region, CHl, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CHl, CH2, and CH3 domains.
- the antibodies of the invention may be from any animal origin including birds and mammals, or derived from phage or ribosome display libraries. Preferably, the antibodies are human, murine (e.g. mouse or rat), donkey, rabbit, goat, guinea pig, camel, horse, or chicken.
- the antibodies of the invention may be monospecific, bispecific, trispecific or of greater multispecificity.
- the antibodies may be labelled in any suitable manner, thus allowing for , detection in a suitable assay.
- one or both of the moieties is a solid support, such as a particle or bead, or magnetic bead, or matrix such as a sheet, gel, filter, membrane, fibre, tube, microtitre plate or column.
- solid supports such as dipsticks, polymers, fibre optics and glass and electronic devices (e.g. diodes and transistors). Such solid supports may either already comprise one or more free amino groups or they may be amino-functionalised.
- one or both moieties is a medicament, for example an antibiotic, antifungal or anticancer agent.
- one or both moieties is a dye, for example, fluorescein, rhodamine or Texas Red.
- the dye is fluorescein.
- one or both moieties is a moiety as - ii - defined above which incorporates a radiolabel.
- the radiolabel may, for example, be 125 I or Europium.
- the molar ratio of the first moiety to the linker in step (i) is preferably in the range 1:45 to 1: 140.
- the molar ratio is chosen to maximise the efficiency of the conjugation without unduly lengthening the overall process time.
- the molar ratio is 1:60 to 1: 120, more preferably 1:80 to 1: 100, and most preferably about 1:90.
- the molar ratio of the second moiety to the first moiety in step (ii) is preferably in the range 1:1 to 8:1.
- the molar ratio is chosen to maximise the efficiency of the conjugation without unduly lengthening the overall process time.
- the molar ratio is 2: 1 to 6: 1, more preferably 3: 1 to 6: 1, and most preferably about 4:1.
- the buffer is chosen as one that is suitable for conjugating the chosen first and second moieties with the chosen linker.
- Suitable buffers are well known in the art.
- the buffer is an aqueous buffer. If the first and/or second moiety is a biological molecule, the buffer should ideally be a physiologically-acceptable buffer.
- suitable aqueous buffers include PBS, borate-based buffers, Tris-HCl, etc. Most preferably, the buffer is a sodium borate buffer.
- One or more co-solvents may also be used, e.g. DMF, DMSO and/or an alcohol, for example ethanol, propanol or butanol.
- the pH will be chosen to maximise the efficiency of the conjugation.
- suitable pHs include pH 5.5 to 9.5. If the first and/or second moiety is a biological molecule, the pH should ideally be a physiologically- acceptable pH, for example pH 6 to 9, more preferably pH 6 to 8.5, most preferably about pH 8.0.
- reaction times for steps (i) and (ii) are chosen to maximise the efficiency of the conjugation without unduly lengthening the overall process time.
- the reaction times for steps (i) and (ii) may the same or different. If times of less than 15 minutes are used, an undesirable amount of linker and first/second moieties may be unreacted. If times of more than 120 minutes are used. polymer formation may occur. Examples of suitable reaction times are about 15, about 30, about 45, about 60, about 75, about 90, about 105 or about 120 minutes. Preferred reaction times are 15 to 45 minutes, 30 to 90 minutes and 45 to 75 minutes. Most preferably, the reaction time is about 30 minutes or about 60 minutes.
- the temperature of the reaction is chosen to maximise the conjugation efficiency.
- the reaction temperatures for steps (i) and (ii) may the same or different. Examples of suitable temperatures are 4 to 50°C.
- reaction temperatures should preferably be kept within physiological ranges, for example between 4 and 37°C.
- reaction temperature is 4-37°C, most preferably about room temperature, e.g. about 21 0 C.
- step (ii) is carried out directly after step (i).
- directly after it is intended to mean that step (ii) is carried out without a delay or intermediate step after step (i) .
- the second moiety when carrying out step (ii), is added to the reaction mixture obtained from step (i), i.e. the first moiety-linker conjugate obtained from step (i) is not purified or is not treated in any other way before the second moiety is added to the reaction mixture.
- step (i) and step (ii) are carried out in a single reaction vessel using the same buffer.
- the conjugate may be purified by any suitable process.
- purification processes include chromatographic means, for example ion exchange, anion/cation exchange chromatography, FPLC or reverse phase, hydrophobic interaction, gel filtration, membrane separation, extraction, gels, capillary electrophoresis, affinity chromatography, precipitation, centrifugation and osmosis.
- Preferred purification processes are anion exchange, gel filtration and membrane separation (e.g. dialysis).
- the conjugate may be purified by FPLC using a Tris/salt gradient.
- the conjugate may be stored, for example at 4° C in 2OmM Tris pH 7.5, 0.1-0.5 M sodium chloride etc. Under such conditions, the conjugate should remain stable for at least 5 months.
- the conjugate may be freeze-dried or lyophilised.
- Stabilising agents such as BSA, antibacteriocides, detergents, surfactants and sugars
- BSA basic monomer sequence polymer sequence polymer sequence polymer sequence polymer sequence polymer sequence polymer sequence polymer sequence
- Preferred conjugates from step (i) are antibody- or enzyme-linker conjugates, particularly those wherein the enzyme is horseradish peroxidase or glucose oxidase, and particularly those wherein the linker is DIDS.
- Further preferred conjugates from step (i) include solid support-linker, for example "activated" beads, dip-sticks, micro-titreplates, polymers, fibre optics, glass and electronic devices.
- Preferred conjugates from step (ii) include enzyme-antibody, enzyme-enzyme, enzyme-oligonucleotide, enzyme-DNA conjugates, enzyme-solid support and antibody-solid support.
- Particularly preferred conjugates include horse-radish peroxidase-antibody and horse-radish peroxidase-oligonucleotide conjugates; glucose oxidase-antibody and glucose oxidase-oligonucleotide conjugates.
- conjugates are horse radish peroxidase-DIDS-antibody and horse-radish peroxidase-DIDS- oligonucleotide conjugates; glucose oxidase-DIDS-antibody and glucose oxidase-DIDS-oligonucleotide conjugates.
- an enzyme is reacted with about a 90 fold molar excess of crosslinker for about 30 minutes.
- the linker-enzyme conjugate is then reacted in about 2.4 fold molar excess (enzyme:antibody) with an antibody for 30 minutes.
- the enzyme is horseradish peroxidase
- the linker is DIDS
- the antibody is an anti- HGG antibody.
- the invention also relates to a process for conjugating a first moiety with a second moiety, as herein defined, which additionally comprises the step of reacting one or more compounds of formula I with a diamine of formula XI:
- the linkers of the invention can be used, for example, to attach DNA or polypeptides to solid supports such as polystyrene beads, plastic wells, magnetic particles, electronics or optical fibres.
- the invention also provides a kit comprising:
- the invention also provides a kit comprising:
- the first-moiety-linker conjugate is preferably in lyophilised or freeze-dried form.
- the coupling buffer is preferably one which is suitable for coupling the first- moiety-linker conjugate to a second moiety, wherein the second moiety comprises one or more free amino groups.
- the coupling buffer is 0. IM sodium borate, pH 8.
- the coupling buffer may be provided in dry or aqueous form.
- the kit optionally includes instructions for coupling the first moiety-linker conjugate to a second moiety.
- the invention also extends to conjugates which are produced using the processes of the current invention.
- the invention further provides a compound of formula II:
- R 1 to R 4 , R 7 to R 10 > R 11 to R 14 and R 17 to R 20 are independently selected from H, halogen, Ci- 10 -alkyl, C 3 - 8 ⁇ cycloalkyl, OH 5 O-d-s-alkyl, SH 3 NH 2 , NO2, CO 2 H, CO 2 -C i-3-alkyl, SO 3 H and SO3X, wherein X denotes a counter ion, for example, ISTHU + , Na + or K + ;
- R 5 , R 6 , R 15 and R 16 are independently selected from H, halogen, Ci-6-alkyl, OH, O-Ci-3-alkyl, SH, NH 2 , CO 2 H, and CO 2 -Ci- 3 -alkyl;
- n and n are each independently 1, 2 or 3
- Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone.
- R 1 to R 4 , R 7 to R 10 , R 11 to R 14 and R 17 to R 20 are each independently selected from H 3 methyl, ethyl and SO3X.
- the invention further provides a compound .of formula IX or X:
- X is NH 4 + , Na + or K + .
- the invention also provides a moiety-linker conjugate, wherein the linker is one of formulae I 5 II, III, IV, V, VI, VII, VIII, IX or X as defined herein.
- the linker is one of formulae I 5 II, III, IV, V, VI, VII, VIII, IX or X as defined herein.
- the moiety is as defined herein.
- the invention also provides a first moiety-linker-second moiety conjugate wherein the linker is one of formulae I, II, III, IV, V, VI, V ⁇ I, VIII, IX or X as defined herein; and wherein the first and/or second moiety is as defined herein.
- the invention also provides a conjugate as defined herein for use as a medicament; and a conjugate as defined herein for use in a diagnostic method practised on the human or animal body.
- the invention also provides the use of a conjugate as defined herein in an ex vivo diagnostic method; and the use of a conjugate as defined herein in the manufacture of a diagnostic tool for use in a diagnostic method practised on the human or animal body.
- the invention further provides the use of a conjugate as defined herein in the manufacture of a medicament for use in a method of treatment of the human or animal body.
- the invention also provides a method of treating a patient comprising administering to that patient a conjugate as defined herein; and a method of diagnosing a condition in a patient comprising administering to that patient a conjugate as defined herein.
- Figure 1 illustrates the purification of a HRP-DIDS-anti-HCG antibody conjugate on an ion exchange column on an Akta Prime liquid
- Figure 2 illustrates the purification of a HRP-DIDS-anti-Inhibin A antibody conjugate on an ion exchange column on an Akta Prime liquid chromatographic system. 25
- Figure 3 illustrates an ELISA of a HRP-DIDS-anti-Inhibin A conjugate of Example 3 in comparison with a commercial standard (control) assay for Inhibin A.
- Figure 4 shows the purification of a HRP-DIDS-oligonucleotide by anion exchange chromatography.
- FIG. 5 illustrates an ELOSA of two HRP-DNA conjugates of the invention.
- the product was purified by anion exchange chromatography using a Q- Sepharose column and AKTA prime chromatography unit. The product was eluted in a gradient of 0 to IM sodium chloride in 2OmM Tris pH 7.5. (Fig
- Antibodies can be linked to amino functionalised beads (for example, polystyrene) using.a similar procedure to that described in Example 1.
- Enzyme antibody conjugates are quality controlled by immunoassay.
- a capture antibody is immobilised on polystyrene beads' and the beads dried onto a membrane (dipstick).
- the immunogen+conjugate dissolved in an elution buffer is then applied to the dipstick and the mixture allowed to run up the stick. Enzyme substrate is added and any signal observed at the application point of the beads is noted.
- HRP-DIDS-anti-Inhibin A (a fertility marker) conjugate was prepared using a similar procedure to that described in Example 1.
- Figure 2 shows the chromatographic (AKTA prime) purification profile obtained.
- This conjugate was quality controlled using the DSL Ltd Inhibin A (DSL-10- 28100) ELISA kit.
- Figure 3 demonstrates the superior performance of the prepared conjugate versus a commercial control in an ELISA for Inhibin A.
- the level of detection of target Inhibin A by the present conjugate was lOpg/ml.
- the commercial product was at least 10 times less sensitive (detection level of 250pg/ml).
- HRP HRP 4B - Batch 947C (50mgs).
- the product was purified by anion exchange chromatography using a Q- Sepharose column and AKTA Prime chromatography unit. The product was eluted in a gradient of 0 to IM sodium chloride in 2OmM Tris pH7.5 ( Figure 4).
- Figure 5 demonstrates the comparative performance in an ELOSA of two HRP-DNA conjugates differing only in the structure of the linker connecting the DNA strand to the enzyme (linker 1 is DIDS 3 linker 2 is DIDS-lysine- DIDS).
- Kit comprising a pre-activated moiety
- a kit comprising (i) a lyophilised or freeze-dried HRP-DIDS conjugate as described in Example 1, and (ii) an aqueous coupling buffer (0. IM sodium borate, pH 8).
- the coupling buffer is added to the lyophilised or freeze- dried HRP-DIDS conjugate.
- An antibody is then added and conjugation is allowed to proceed for 0.5 hours.
- the reaction is stopped by the addition of 20 mM Tris/HCl, pH 7.5.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a process for linking a first moiety with a linker and to cross-linking a first moiety such as a nucleic acid or protein with a second moiety such as an antibody or enzyme. In preferred embodiments of the invention, the linker is diisothiocyanatostilbenedisulphonic acid (DIDS) or a dimer thereof.
Description
88702-02pct.632
PROCESS FOR CROSS-LINKING MOIETIES
The invention relates to a linkers for linking moieties such as nucleic acids, proteins, antibodies and polypeptides with other moieties such as enzymes, antibodies and solid supports, and processes using such linkers.
Crosslinking reagents are often used in the diagnostic, pharmaceutical, chemical, electronic and biotechnology industries to produce conjugates such as DNA and antibodies with enzymes, and proteins with biotin. These conjugates' find applications as nucleic acid probes and in immunoassays, amongst others. Crosslinking reactions are also used in the immobilisation of macromolecules on solid supports such as glass, microprocessors, membranes, dipsticks and magnetic beads.
A number of crosslinking reagents and methods are known in the prior art. For example, Pierce market a kit for controlled protein-protein crosslinking which depends on the reaction of a thiol with a maleiimide group (Perbio Science UK 05/06, Pierce 23456) and disuccinimidyl suberate, a homobifunctional agent (Pierce 21655). Other reagents include the photoactivatable sulfo-SANPAH (sulfosuccinimidyl 6-(4'-aizido-2'-nitro- phenylamino)hexanoate) .
A key disadvantage of the methods mentioned above is that the thiol/maleiimide approach is an all-day procedure requiring several complicated steps using unstable reagents. In particular, the thiols readily oxidise and dimerise, and the maleiimides can hydrolyse. Furthermore, the homobifunctional reagents suffer from self-conjugation and polymerisation. Additionally, rapid hydrolysis leading to poor yields and the required use of high concentrations of such toxic reagents are also disadvantages, Photoactivatable reagents also show poor discrimination and are often low yielding.
There exists a need therefore for processes for linking moieties such as macromolecules which do not suffer from the above disadvantages.
The Applicant has now developed an improved method for the conjugation of moieties such as biological macromolecules. This method takes less time than prior art methods; and all reactions steps can be carried out in a single reaction vessel using a single buffer without the need to purify intermediates. High concentrations of toxic reagents are avoided using the method of the invention. Furthermore, the final conjugate may be easily purified using standard means.
The invention therefore provides linkers which are suitable for linking a first moiety with a second moiety and processes using such linkers. The invention also provides "activated" first moieties which comprise first moieties conjugated to linkers of the invention in a form in which they can be used for conjugation to a second moiety, and processes for the production of such "activated" moieties.
The invention therefore provides a process for linking a first moiety with a linker, wherein the first moiety comprises one or more free amino groups and wherein the first moiety is not a cell membrane or cell membrane fraction, the process comprising the steps: ,
(i) conjugating the first moiety with a linker of formula I:
R1 to R4, R7 to R10 ' R11 to R14 and R17 to R20 are independently selected from H3 halogen, Ci-io-alkyϊ, Cs-s-cycloalkyl, OH, O-Ci-3-alkyl, SH, NH2, NO2, CO2H,
SO3H and SO3X3 wherein X denotes a counter ion, for example, NH4 +, Na+ or K+;
R5, R6, R15 and R16 are independently selected from H3 halogen, Ci-β-alkyl, OH3 O-Ci-3-alkyl, SH3 NH23 CO2H3 and CO2-C i-3-alkyl3
m and n are independently I3 2 or 3, and
Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone.
The invention further relates to a process for conjugating a first moiety with a second moiety, wherein the first and second moieties independently comprise one or more free amino groups, the process comprising the steps:
(i) conjugating the first moiety with a linker of formula I:
R1 to R4, R7 to R10, R11 to R14 and R17 to R20 are independently selected from
H3 halogen, Ci-ip-alkyl, C3-8-cycloalkyl, OH3 O-Ci-3-alkyl3 SH3 NH2, NO2, CO2H3 CO2-C i-3-alkyl, SO3H and SO3X3 wherein X denotes a counter ion, for example3 NH4 +, Na+ or K+;
R5 3 R6 3 R15 and R16 are independently selected from H3 halogen, Ct-e-alkyl,
OH3 O-Ci-3-alkyl, SH3 NH23 CO2H3 and CCVC.-s-alkyl;
m and n are independently I3 2 or 3, and
Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone,
and then
(ii) reacting the first moiety-linker conjugate formed in (i) with the second moiety.
Preferably, step (i) is carried out under the conditions:
molar ratio of first moiety: linker 1:45 to 1:140; and/or time 15 to 120 minutes.
Preferably, step (ii) is carried out under the conditions:
molar ratio of first moiety used in step (i):second moiety 1: 1 to 1:8; and/or time 15 to 120 minutes.
In the context of the present invention, the following definitions are used both hereinbefore and hereinafter:
is meant one double bond or a plurality of up to n conjugated double bonds wherein each pair of R5 and R6 groups may, independently of any other R5 and R6 pairs, be either in the cis or in the trans geometrical isomeric configuration; and wherein each R5 may be the same or different, and wherein each R6 may be the same or different. The same applies, mutatis mutandis, to groups comprising R15 and R16 and m.
The term Ci-io-alkyl denotes a branched or unbranched alkyl group having between 1 and 10 carbon atoms. The group includes methyl, ethyl, n-propyl, wσ-propyl, w-butyl, x'so-butyl, sec-butyl, tert-butyl etc.
The term C3-s-cycloalkyl denotes a cyclic alkyl group having between 3 and 8 carbon atoms in the ring. The group includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
The term O-Ch-3-alkyl denotes an alkoxy group having between 1 and 3 carbon atoms in the alkyl portion. The group includes methoxy, ethoxy, n- propoxy and wσ-propoxy.
The term CO2-Ci-3-alkyl denotes an ester group having between 1 and 3 carbqn atoms in the alkyl portion. The group includes methyl carboxylate, ethyl carboxylate, rø-propyl carboxylate and wσ-propyl carboxylate.
The term halogen denotes an atom of a group VII element selected from among fluorine, chlorine, bromine and iodine.
The term "free amino group (s)" refers to amino groups which are capable of reacting with the isothiocyanate groups of the linker. Examples of such free amino groups include those present in the amino acids lysine, arginine, asparagine and glutamine of polypeptides or at the N terminus of polypeptides.
Preferably, R1 to R4, R7 to R10, R11 to R14 and R17 to R20 are each independently selected from H, methyl, ethyl and SO3X.
Preferably, R5, R6, R15 and R16 are each independently selected from H and Ci-3 alkyl.
In some embodiments of the invention, only one or two of R1 to R4 and R7 to R10 are SO3X. Particularly preferably, only one of R1 to R4 and/or only one of R7 to R10 are SO3X. Most preferably, only one of R1 to R4 and/or only one of R7 to R10 are SO3X wherein R4 is SO3X and/or R7 is SO3X.
In other embodiments of the invention, only one or two of R11 to R14 and R17 to R20 are SO3X. Particularly preferably, only one of R11 to R14 and/or only one of R17 to R20 are SO3X. Most preferably, only one of R11 to R14 and/or only one of R17 to R20 are SO3X wherein R14 is SO3X and/or R17 is SO3X.
m and n are preferably 1. If n = 1, then R5 and R6 are preferably arranged in the trans configuration. If m=l, then R15 and R16 are preferably arranged in the trans configuration.
X is preferably Na+.
In some embodiments of the invention, the linker is a compound of formula III:
or a dimerised linker of formula IV
or a compound of formula V
or a dimerised linker of formula VI, VII or VIII:
wherein the R groups, X, m and n are as defined above.
In the compounds of formulae III-VIII, R1 to R20, where present, are preferably independently selected from H, methyl and ethyl. Most preferably, R1 to R20, when present, are all H.
A particularly preferred linker is 4,4'-diisothiocyanato-2,2'-stilbenedisulfonic acid (DIDS, Aldrich 28,561-7). The corresponding dimerised linker (i.e. the compound of formula IV, wherein R1 to R3, R5, R6, R8 to R10, Rn to R13, R15, R16 and R18 to R20 are all H, and n and m are both 1) is also particularly preferred.
The organic linker Y is preferably a linear C2-6-alkyl, most preferably C2-4- alkyl group, optionally substituted at one or more of the backbone carbon atoms by one or more groups selected from halogen, Ci-3-alkyl, O-Ci-3-alkyl, CO2H and CO2-Ci-3-alkyl.
In one particularly preferred embodiment, Y is -CH2CH2-.
In another particularly preferred embodiment, Y is -(CHa)4CH(COOH)-.
In particularly preferred embodiments, the dimerised linkers are selected from the compounds of general formulae IX and X:
wherein X is as defined above.
In the present invention, the first and second moieties, which may be the same or different, are preferably a chemical entity and/or a solid support.
Preferably, the chemical entity is an isolated or purified Chemical entity. Examples of chemical entities include macromolecules, most preferably biological macromolecules. Examples of biological macromolecules include nucleic acid molecules, proteins, polypeptides and peptides. Preferably, the biological macromolecule is in isolated or purified form, e.g. an isolated nucleic acid molecule or a purified protein, polypeptide or peptide. Examples of nucleic acid molecules include DNA and RNA. The nucleic acid molecule may be single-stranded or double-stranded or part single- and part double- stranded. In some preferred embodiments of the invention, the macromolecule is a single-stranded oligomer, preferably a DNA oligomer. Examples of proteins and polypeptides include enzymes and antibodies. Preferably the enzyme is an enzyme which is capable of -producing a detectable reaction, such as horseradish peroxidase, alkaline phosphatase, beta galactosidase, glucose oxidase or a restriction enzyme.
In some embodiments of the invention, the first and/or second moiety is not a cell membrane or a cell membrane fraction. By the term "cell membrane or cell membrane fraction" is meant that the first and/or second moiety is not a biological cell membrane (e.g. a membrane from a red blood cell) or a fraction therefore, for example a fraction that has been obtained by centrifugation of the cell membrane in a solvent. In other embodiments, the first and/or second moiety is not a cell membrane protein, in particular not an anion channel protein.
The first and/or second moieties may also be a structural binding peptide such as streptavidin or avidin, or a label, such as biotin.
In some embodiments of the invention, one or both of the moieties may be an antibody. The antibodies may be of any suitable source, e.g. monoclonal, polyclonal, chimeric, bispecific, single-chain or fragments thereof. Antibody fragments include, but are not limited to. Fab, Fab' and F(ab')2, Fd, single- chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region (s) alone or in combination with the entirety or a portion of the following: hinge region, CHl, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CHl, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals, or derived from phage or ribosome display libraries. Preferably, the antibodies are human, murine (e.g. mouse or rat), donkey, rabbit, goat, guinea pig, camel, horse, or chicken. The antibodies of the invention may be monospecific, bispecific, trispecific or of greater multispecificity.
The antibodies may be labelled in any suitable manner, thus allowing for , detection in a suitable assay.
In other embodiments of the invention, one or both of the moieties is a solid support, such as a particle or bead, or magnetic bead, or matrix such as a sheet, gel, filter, membrane, fibre, tube, microtitre plate or column. Other examples of solid supports according to the invention are dipsticks, polymers, fibre optics and glass and electronic devices (e.g. diodes and transistors). Such solid supports may either already comprise one or more free amino groups or they may be amino-functionalised.
In some embodiments of the invention, one or both moieties is a medicament, for example an antibiotic, antifungal or anticancer agent.
In other embodiments of the invention, one or both moieties is a dye, for example, fluorescein, rhodamine or Texas Red. Preferably the dye is fluorescein.
In yet other embodiments of the invention, one or both moieties is a moiety as
- ii - defined above which incorporates a radiolabel. The radiolabel may, for example, be 125I or Europium.
The molar ratio of the first moiety to the linker in step (i) is preferably in the range 1:45 to 1: 140. The molar ratio is chosen to maximise the efficiency of the conjugation without unduly lengthening the overall process time. Preferably, the molar ratio is 1:60 to 1: 120, more preferably 1:80 to 1: 100, and most preferably about 1:90.
The molar ratio of the second moiety to the first moiety in step (ii) is preferably in the range 1:1 to 8:1. The molar ratio is chosen to maximise the efficiency of the conjugation without unduly lengthening the overall process time. Preferably, the molar ratio is 2: 1 to 6: 1, more preferably 3: 1 to 6: 1, and most preferably about 4:1.
The buffer is chosen as one that is suitable for conjugating the chosen first and second moieties with the chosen linker. Suitable buffers are well known in the art. Preferably the buffer is an aqueous buffer. If the first and/or second moiety is a biological molecule, the buffer should ideally be a physiologically-acceptable buffer. Examples of suitable aqueous buffers include PBS, borate-based buffers, Tris-HCl, etc. Most preferably, the buffer is a sodium borate buffer.
One or more co-solvents may also be used, e.g. DMF, DMSO and/or an alcohol, for example ethanol, propanol or butanol.
The pH will be chosen to maximise the efficiency of the conjugation. Examples of suitable pHs include pH 5.5 to 9.5. If the first and/or second moiety is a biological molecule, the pH should ideally be a physiologically- acceptable pH, for example pH 6 to 9, more preferably pH 6 to 8.5, most preferably about pH 8.0.
The reaction times for steps (i) and (ii) are chosen to maximise the efficiency of the conjugation without unduly lengthening the overall process time. The reaction times for steps (i) and (ii) may the same or different. If times of less than 15 minutes are used, an undesirable amount of linker and first/second moieties may be unreacted. If times of more than 120 minutes are used.
polymer formation may occur. Examples of suitable reaction times are about 15, about 30, about 45, about 60, about 75, about 90, about 105 or about 120 minutes. Preferred reaction times are 15 to 45 minutes, 30 to 90 minutes and 45 to 75 minutes. Most preferably, the reaction time is about 30 minutes or about 60 minutes.
The temperature of the reaction is chosen to maximise the conjugation efficiency. The reaction temperatures for steps (i) and (ii) may the same or different. Examples of suitable temperatures are 4 to 50°C.
If the first and/or second moiety is a biological molecule, reaction temperatures should preferably be kept within physiological ranges, for example between 4 and 37°C. Preferably the reaction temperature is 4-37°C, most preferably about room temperature, e.g. about 210C.
In one preferred embodiment of the invention, step (ii) is carried out directly after step (i). By the term "directly after", it is intended to mean that step (ii) is carried out without a delay or intermediate step after step (i) .
In other preferred embodiments of the invention, when carrying out step (ii), the second moiety is added to the reaction mixture obtained from step (i), i.e. the first moiety-linker conjugate obtained from step (i) is not purified or is not treated in any other way before the second moiety is added to the reaction mixture.
Preferably, both step (i) and step (ii) are carried out in a single reaction vessel using the same buffer.
At the end of the conjugation process, the conjugate may be purified by any suitable process. Examples of purification processes include chromatographic means, for example ion exchange, anion/cation exchange chromatography, FPLC or reverse phase, hydrophobic interaction, gel filtration, membrane separation, extraction, gels, capillary electrophoresis, affinity chromatography, precipitation, centrifugation and osmosis. Preferred purification processes are anion exchange, gel filtration and membrane separation (e.g. dialysis).
For example, the conjugate may be purified by FPLC using a Tris/salt
gradient.
After purification, the conjugate may be stored, for example at 4° C in 2OmM Tris pH 7.5, 0.1-0.5 M sodium chloride etc. Under such conditions, the conjugate should remain stable for at least 5 months.
Alternatively, the conjugate may be freeze-dried or lyophilised. Stabilising agents (such as BSA, antibacteriocides, detergents, surfactants and sugars) may also be added to the conjugates (either in solution, freeze-dried or lyophilised).
Preferred conjugates from step (i) are antibody- or enzyme-linker conjugates, particularly those wherein the enzyme is horseradish peroxidase or glucose oxidase, and particularly those wherein the linker is DIDS. Further preferred conjugates from step (i) include solid support-linker, for example "activated" beads, dip-sticks, micro-titreplates, polymers, fibre optics, glass and electronic devices.
Preferred conjugates from step (ii) include enzyme-antibody, enzyme-enzyme, enzyme-oligonucleotide, enzyme-DNA conjugates, enzyme-solid support and antibody-solid support. Particularly preferred conjugates include horse-radish peroxidase-antibody and horse-radish peroxidase-oligonucleotide conjugates; glucose oxidase-antibody and glucose oxidase-oligonucleotide conjugates. Specific examples of particularly preferred conjugates are horse radish peroxidase-DIDS-antibody and horse-radish peroxidase-DIDS- oligonucleotide conjugates; glucose oxidase-DIDS-antibody and glucose oxidase-DIDS-oligonucleotide conjugates.
In one particularly preferred embodiment of the invention, an enzyme is reacted with about a 90 fold molar excess of crosslinker for about 30 minutes.
The linker-enzyme conjugate is then reacted in about 2.4 fold molar excess (enzyme:antibody) with an antibody for 30 minutes. Preferably, the enzyme is horseradish peroxidase, the linker is DIDS, and the antibody is an anti- HGG antibody.
The invention also relates to a process for conjugating a first moiety with a second moiety, as herein defined, which additionally comprises the step of
reacting one or more compounds of formula I with a diamine of formula XI:
XI
H2N NH2
wherein Y is as defined above, in order to produce a dimerised linker of formula II.
• The linkers of the invention can be used, for example, to attach DNA or polypeptides to solid supports such as polystyrene beads, plastic wells, magnetic particles, electronics or optical fibres.
The invention also provides a kit comprising:
(a) a linker of any one of formulae I, III, and V as herein defined; and
(b) a diamine of formula XI as herein defined.
The invention also provides a kit comprising:
(i) a first moiety-linker conjugate, wherein the linker is of any one of formulae I, II, III, IV, V, VI, VII, VIII, IX or X; and (ii) a coupling buffer.
The first-moiety-linker conjugate is preferably in lyophilised or freeze-dried form.
The coupling buffer is preferably one which is suitable for coupling the first- moiety-linker conjugate to a second moiety, wherein the second moiety comprises one or more free amino groups. Most preferably, the coupling buffer is 0. IM sodium borate, pH 8. The coupling buffer may be provided in dry or aqueous form.
The kit optionally includes instructions for coupling the first moiety-linker conjugate to a second moiety.
The invention also extends to conjugates which are produced using the processes of the current invention.
The invention further provides a compound of formula II:
wherein
R1 to R4, R7 to R10> R11 to R14 and R17 to R20 are independently selected from H, halogen, Ci-10-alkyl, C3-8~cycloalkyl, OH5 O-d-s-alkyl, SH3 NH2, NO2, CO2H, CO2-C i-3-alkyl, SO3H and SO3X, wherein X denotes a counter ion, for example, ISTHU+, Na+ or K+;
R5, R6, R15 and R16 are independently selected from H, halogen, Ci-6-alkyl, OH, O-Ci-3-alkyl, SH, NH2, CO2H, and CO2-Ci-3-alkyl;
m and n are each independently 1, 2 or 3, and
Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone.
Preferably, R1 to R4, R7 to R10, R11 to R14 and R17 to R20 are each independently selected from H3 methyl, ethyl and SO3X.
The invention further provides a compound .of formula IX or X:
wherein X is NH4 +, Na+ or K+.
The invention also provides a moiety-linker conjugate, wherein the linker is one of formulae I5 II, III, IV, V, VI, VII, VIII, IX or X as defined herein. Preferably, the moiety is as defined herein.
The invention also provides a first moiety-linker-second moiety conjugate wherein the linker is one of formulae I, II, III, IV, V, VI, VΪI, VIII, IX or X as defined herein; and wherein the first and/or second moiety is as defined herein.
The invention also provides a conjugate as defined herein for use as a medicament; and a conjugate as defined herein for use in a diagnostic method practised on the human or animal body.
The invention also provides the use of a conjugate as defined herein in an ex vivo diagnostic method; and the use of a conjugate as defined herein in the manufacture of a diagnostic tool for use in a diagnostic method practised on the human or animal body.
The invention further provides the use of a conjugate as defined herein in the manufacture of a medicament for use in a method of treatment of the human or animal body.
The invention also provides a method of treating a patient comprising administering to that patient a conjugate as defined herein; and a method of diagnosing a condition in a patient comprising administering to that patient a conjugate as defined herein.
The following abbreviations are used throughout this specification:
BSA Bovine serum albumin
DIDS 4,4'-diisothiocyanato-2j2'-stilbenedisulfonic acid
5 DMF Dimethylformamide
DMSO Dimethyl sulfoxide
ELISA Enzyme-linked immuno-sorbent assay
ELOSA Enzyme-linked oligo-sorbent assay
FPLC fast protein liquid chromatography
10 HCG human chorionic gonadotropin
HPLC High performance liquid chromatography
HRP horseradish peroxidase
PBS phosphate-buffered saline
Tris tris (hydroxymethyl) aminomethane •15
BRIEF DESCRIPTION OF FIGURES
Figure 1 illustrates the purification of a HRP-DIDS-anti-HCG antibody conjugate on an ion exchange column on an Akta Prime liquid
20 chromatographic system.
Figure 2 illustrates the purification of a HRP-DIDS-anti-Inhibin A antibody conjugate on an ion exchange column on an Akta Prime liquid chromatographic system. 25
Figure 3 illustrates an ELISA of a HRP-DIDS-anti-Inhibin A conjugate of Example 3 in comparison with a commercial standard (control) assay for Inhibin A.
30 Figure 4 shows the purification of a HRP-DIDS-oligonucleotide by anion exchange chromatography.
Figure 5 illustrates an ELOSA of two HRP-DNA conjugates of the invention.
EXAMPLES
Example 1
Preparation of HRP-DIDS-anti-HCG antibody conjugate
Materials
Monoclonal anti-HCG antibody, British Biocell International, batch 7416, 5.3 mgs/ml.
Crosslinking agent DIDS, Aldrich 285617. Horse radish peroxidase, Bio2yme Labs, code HRP 4B, Batch 935 C Sodium Borate buffer pH 8, 0.1 M
Reagent concentrations
Reagent m.wt mass(mg) moles in reaction
HRP 40000 0.27 6.8 nmol
DIDS 498 0.3 0.6 μmol
ANTIBODY 150000 0.4 2.7 nmol
Protocol
To the HRP dissolved in borate buffer (45μl) was added DIDS in borate buffer (5μl). The reaction mixture was shaken for 0.5 hours and then the antibody (75.6μl of supplied solution + 124μl borate buffer) was added and the shaking continued for a further 0.5 hours. ■
The product was purified by anion exchange chromatography using a Q- Sepharose column and AKTA prime chromatography unit. The product was eluted in a gradient of 0 to IM sodium chloride in 2OmM Tris pH 7.5. (Fig
1).
Example 2
Preparation of bead-DIDS-anti-HCG antibody conjugate
Antibodies can be linked to amino functionalised beads (for example, polystyrene) using.a similar procedure to that described in Example 1.
Materials
Polyscience amino-functionalised polystyrene beads 2μm.
Lot GK002050 IT, 50mg/ml, 4nmol of amine/mg.
DIDS and antibody as Example 1.
Protocol
1 mg of beads contained in a ImI Eppendorf tube(with the cap removed and placed in a FALCON tube) were washed with borate buffer (2x300μl) and concentrated by centrifugation (2000rpm, 4 minutes per buffer wash). To the concentrated beads was added 200μg DIDS dissolved in 50μl borate buffer. The mixture was shaken at 50 revolutions per minute for 1 hour and then washed with borate buffer (2x300μl ) and concentrated. 20μl (O.lmg) of antibody in 80μl borate buffer was added to the beads and the mixture shaken for a further 1 hour. The conjugated beads were washed with borate buffer (2x300μl) and then stored at 4°C in 2OmM Tris pH 7.5.
Enzyme antibody conjugates are quality controlled by immunoassay. A capture antibody is immobilised on polystyrene beads' and the beads dried onto a membrane (dipstick). The immunogen+conjugate dissolved in an elution buffer is then applied to the dipstick and the mixture allowed to run up the stick. Enzyme substrate is added and any signal observed at the application point of the beads is noted.
Example 3
Preparation of HRP-DIDS-anti-Inhibin A conjugate
An HRP-DIDS-anti-Inhibin A (a fertility marker) conjugate was prepared using a similar procedure to that described in Example 1. Figure 2 shows the chromatographic (AKTA prime) purification profile obtained.
This conjugate was quality controlled using the DSL Ltd Inhibin A (DSL-10- 28100) ELISA kit. Figure 3 demonstrates the superior performance of the prepared conjugate versus a commercial control in an ELISA for Inhibin A.
The level of detection of target Inhibin A by the present conjugate was lOpg/ml. In comparison, the commercial product was at least 10 times less sensitive (detection level of 250pg/ml).
Example 4
Preparation of HRP-DIDS-oligonucleotide
Materials
Amino-link oligonucleotide to DNA target:
Amine-30mer oligonucleotide in EbO, lOOμM, HPLC purified (Sigma
Genosys);
Cross linking reagent: DIDS;
HRP: HRP 4B - Batch 947C (50mgs); and
Sodium Borate buffer pHδ.O, 0.1M.
Reagent concentrations
Reagent m.wt. mass(mgs) mols in PW Sodium borate buffer vol
HRP 40000 0.675 17nmols 45μl
DIDS 498. 0.75 1.5μmol 5μl
Amino-linked oligonucleotide 9395 0.063 6.7nmols 67μl (or 134μl for 2x)
Protocol
To the HRP dissolved in sodium borate (45μl) was added the coupling agent DIDS in borate buffer (5μl). The reaction mixture was shaken for 0.5 hours and the oligonucleotide (67μl or 134μl for 2x) was added and the shaking continued for a further 0.5 hours (total volume =117μl or 184μl). 2OmM Tris pH 7.5 (250μl) was added to stop the reaction.
The product was purified by anion exchange chromatography using a Q- Sepharose column and AKTA Prime chromatography unit. The product was eluted in a gradient of 0 to IM sodium chloride in 2OmM Tris pH7.5 (Figure 4).
Figure 5 demonstrates the comparative performance in an ELOSA of two HRP-DNA conjugates differing only in the structure of the linker connecting the DNA strand to the enzyme (linker 1 is DIDS3 linker 2 is DIDS-lysine- DIDS).
Application of linker 1 led to a level of detection of 400pg/ml (lfmol of target).
Example 5
Kit comprising a pre-activated moiety
A kit is produced comprising (i) a lyophilised or freeze-dried HRP-DIDS conjugate as described in Example 1, and (ii) an aqueous coupling buffer (0. IM sodium borate, pH 8).
At the time of use, the coupling buffer is added to the lyophilised or freeze- dried HRP-DIDS conjugate. An antibody is then added and conjugation is allowed to proceed for 0.5 hours. The reaction is stopped by the addition of 20 mM Tris/HCl, pH 7.5.
Claims
1. A process for linking a first moiety with a linker, wherein the first moiety comprises one or more free amino groups and wherein the first moiety is a not a cell membrane or cell membrane fraction, the process comprising the steps:
(i) conjugating the first moiety with a linker of formula I:
or a dimerised linker of formula II:
wherein
R1 to R4, R7 to R10' R11 to R14 and R17 to R20 are independently selected from H5 halogen, d-io-alkyl, C3-8-cycloalkyl, OH, O-Ch-3-alkyl, SH, NH2, NO2, CO2H, CO2-Ci-3~alkyl, SO3H and SO3X, wherein X denotes a counter ion, for example, NH4 +, Na+ or K+;
R5, R6, R15 and R16 are independently selected from H, halogen, d-e-alkyl, OH, O-Ci-3-alkyl, SH, NH2, CO2H, and CO2-C 1-3-alkyl; m and n are independently I3 2 or 3, and
Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone.
2. A process for conjugating a first moiety with a second moiety, wherein the first and second moieties independently comprise one or more free amino groups, the process comprising the steps:
(i) conjugating the first moiety with a linker of formula I:
or a dimerised linker of formula II:
wherein
R1 to R4, R7 to R10> Rn to R14 and R17 to R20 are independently selected from H3 halogen, Ci-io-alkyl, C3.8-cycloalkyl3 OH, O-d-3-alkyl, SH, NH2, NO2, GO2H, C^-Cw-alkyl, SO3H and SO3X, wherein X denotes a counter ion, for example, NH4 +, Na+ or K+; R5, R6j R15 and R16 are independently selected from H3 halogen, Ci-6-alkyl, OH3 O-Ci-3-alkyl, SH3 NH2, CO2H3 and CO2-Ci-3-alkyl,
m and n are independently I3 2 or 33 and
Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone3
and then
(ii) reacting the first moiety-linker conjugate formed in (i) with the second moiety.
3. A process as claimed in claim 1 or claim 23 wherein step (i) is carried out under the conditions:
molar ratio of first moiety: linker 1:45 to 1:140.
4. A process as claimed in claim 1 or claim 2 or claim 33 wherein step (i) is carried out under the conditions:
time 15 to 120 minutes
5. A process as claimed in any one of claims 2 to 4, wherein step (ii) is carried out under the conditions:
molar ratio of first moiety used in step (i):second moiety 1:1 to 1:8.
6. A process as claimed in any one of claims 2 to 53 wherein step (ii) is carried out under the conditions:
time 15 to 120 minutes.
7. A process as claimed in any one of claims 1 to 6, wherein R1 to R4 3 R7 to R10, R11 to R14 and R17 to R20 3 when present, are each independently selected from H3 methyl, ethyl and SO3X.
8. A process as claimed in any one of claims 1 to 7, wherein R5, R6, R15 and R16 J when present, are each independently selected from H and C1-3 alkyl.
9. A process as claimed in any one of claims 1 to 8, wherein only one or two of R1 to R4 and R7 to R10 are SO3X.
10. A process as claimed in claim 9, wherein only one of R1 to R4 and/or only one of R7 to R10 are SO3X.
11. A process as claimed in claim 1O3 wherein R4 is SO3X and/or R7 is SO3X.
12. A process as claimed in any one of claims 1 to 11, wherein only one or two of R11 to R14 and R17 to R20 3 when present, are SO3X.
13. A process as claimed in claim 123 wherein only one of R11 to R14 and/or only one of R17 to R20 3 when present, are SO3X.
14. A process as claimed in claim 13, wherein R14 is SO3X and/or R17 is SO3X.
15. A process as claimed in any one of claims 1 to 14, wherein n is 1.
16. A process as claimed in claim 153 wherein R5 and R6 are arranged in the trans configuration.
17. A process as claimed in any one of claims 1 to 16, wherein m is 1.
18. A process as claimed in claim 173 wherein R15 and R16 are arranged in the trans configuration.
19. A process as claimed in any one of claims 1 to 18, wherein X is Na+.
20. A process as claimed in any one of claims 1 to 19, wherein the linker is a compound of formula III:
or a dimerised linker of formula IV
or a linker of formula V
21. A process as claimed in claim 2O3 wherein R1 to R20, when present, are independently selected from H3 methyl and ethyl.
22. A process as claimed in claim 20, wherein R1 to R20, when present, are all H.
23. A process as claimed in any one of claims 1 to 223 wherein the organic linker Y is a linear C2-6-alkyl3 most preferably a C2-4-alkyl group, optionally substituted at one or more of the backbone carbon atoms by one or more groups selected from halogen, Ci-3-alkyl, O-Ci-3-alkyl, CO2H and CO2-C1-3- alkyl.
24. A process as claimed in claim 23, wherein Y is -CH2CH2-.
25. A process as claimed in claim 23, wherein Y is -(CH2^CH(COOH)-.
26. A process as claimed in any one of claims 1 to 6 wherein the linker is 434'-diisothiocyanato-2,2'-stilbenedisulfonic acid, disodium salt (DIDS):
27. A process as claimed in any one of claims 1 to 25, wherein the dimerised linker is selected from compounds of formulae IX and X:
X
28. A process as claimed in any one of claims 1 to 27, wherein the first moiety and/or the second moiety are independently selected from a chemical entity, preferably an isolated or purified chemical entity, and a solid support.
29. A process as claimed in any one of claims 1 to 28, wherein the first moiety and/or the second moiety is a macromolecule, preferably a biological macromolecule and most preferably an isolated or purified biological macromolecule.
30. A process as claimed in claim 29, wherein the first moiety and/or the second moiety are independently selected from a nucleic acid molecule, a protein, a polypeptide or a peptide.
31. A process as claimed in claim 30, wherein at least one of the moieties is a DNA oligomer, an enzyme or an optionally-labelled antibody.
32. A process as claimed in claim 31, wherein at least one of the moieties is horseradish peroxidase, alkaline phosphatase, beta galactosidase, glucose oxidase or a restriction enzyme. ■
33. A process as claimed in any one of claims 1 to 32, wherein the moiety or at least one moiety is a solid support, such as a particle, a bead or a matrix such as a sheet, gel, filter, membrane, fibre, tube, microtitre plate or column.
34. A process as claimed in any one of claims 1 to 33, wherein at least one moiety is a medicament or a dye.
35. A process as claimed in any one of claims 1 to 34, wherein at least one moiety incorporates a radiolabel.
36. A process as claimed in any one of the preceding claims, wherein the molar ratio of the first moiety:linker is 1:60 to 1: 120, more preferably 1:80 to 1:100, and most preferably about 1:90.
37. A process as claimed in any one of claims 2 to 36, wherein the molar ratio of the second moiety to the first moiety is 2: 1 to 6: 1, more preferably 3:1 to 6: 1, and most preferably about 4: 1.
38. A process as claimed in any one of the preceding claims, wherein the process is carried out at a pH between 5.5 to 9.5.
39. A process as claimed in any one of the preceding claims, wherein the reaction time for step (i) is 15 to 45 minutes, 30 to 90 minutes or 45 to 75 minutes.
40. A process as claimed in any one of claims 2 to 39, wherein the reaction time for step (ii) is 15 to 45 minutes, 30 to 90 minutes or 45 to 75 minutes.
41. A process as claimed in any one of the preceding claims, wherein the reaction (s) are carried out at 4 to 5O0C.
42. A process as claimed in any one of claims 2 to 41, wherein step (ii) is carried out directly after step (i).
43. A process as claimed in any one of claims 2 to 42, wherein, when carrying out step (ii), the second moiety is added to the reaction mixture obtained from step (i).
44. A process as claimed in any one of claims 2 to 43, wherein the first moiety-linker conjugate obtained from step (i) is not purified or is not treated in any other way before the second moiety is added to the reaction mixture.
45. A process as claimed in any one of the preceding claims, wherein the process additionally comprises step (ia) purifying the obtained first moiety- linker conjugate from, step (i), and optionally resuspending the conjugate in a suitable buffer.
46. A process as claimed in any one claims 2 to 45, wherein the process additionally comprises step (iia) purifying the obtained conjugate, and optionally resuspending the conjugate in a suitable buffer. ■
47. A process as claimed in claim 45, wherein the conjugate is an enzyme- linker conjugate.
48. A process as claimed in any one of claims 2-44 and 46, wherein the conjugate is an enzyme-antibody, enzyme-enzyme, enzyme-oligonucleotide or enzyme-DNA conjugate.
49. A process as claimed in claim 47 or claim 48 wherein the enzyme is horseradish peroxidase.
50. A process as claimed in claim 47 or claim 48 wherein the enzyme is glucose oxidase.
51. A process as claimed in claim 48 or claim 49 or claim 50 wherein the antibody is an anti-HCG antibody.
52. A process as claimed in any one of claims 2-44 and 46, wherein an enzyme is reacted with about a 90 fold molar excess of linker for about 30 minutes; and then the linker-enzyme conjugate is reacted in about 2.4 fold molar excess (enzyme:antibody) with an antibody for about 30 minutes.
53. A process as claimed in any one of the preceding claims, which additionally comprises the step of reacting one or more compounds of formula I with a diamine of formula XI:
XI
-Y.
H9N NH,
in order to produce a dimerised linker of formula II.
54. A compound of formula II:
wherein
R1 to R4 3 R7 to R10> Rπ to R14 and R17 to R20 are independently selected from H3 halogen, Ci-io-alkyl, C3-8-cycloalkyl, OH, O-Ci-3-alkyl, SH3 NH2, NO2, GO2H3 SO3H and SO3X, wherein X denotes a counter ion, for example, NH4+ 3 Na+ or K+;
R5, R6 3 R15 and R16 are independently selected from H, halogen, Ci-6-alkyl, OH, O-Ci-3-alkyl, SH, NH2, CO2H, and CO2-C 1-3-alkylj
m and n are each independently 1, 2 or 3, and
Y denotes an organic linker with between 2 and 10 carbon atoms in the backbone.
55. A compound as claimed in claim 54, wherein R1 to R4 3 R7 to R10, Ru to R14 and R17 to R20 are each independently selected from H, methyl3 ethyl and SO3X.
56. A compound of formula IX or X:
wherein X is NH4+ 3 Na+ or K+.
57. A kit comprising:
(a) a linker of formula I, III or V as defined in any one of claims 1 to 22 and 26; and (b) a diamine as defined in any one of claims 23 to 25.
58. A kit comprising:
(i) a moiety-linker conjugate, wherein the linker is one of formulae I3 II, IH3 IV3 V3 VI3 VII3 VIII3 IX or X as defined in any one of claims I3 23 7-353 47- 51; and (ii) a coupling buffer.
59. A kit as claimed in claim 583 wherein the moiety-linker conjugate is present in lyophilised form.
60. A kit as claimed in claim 58 or 593 wherein the moiety is as defined in any one of claims 28-35 or 47-51.
61. A conjugate produced by or producable by a process of any one of claims 1 to 53.
62. A moiety-linker conjugate, wherein the linker is one of formulae I3 H3 IH3 IV3 V3 VI3 VII3 VIII3 IX or X as defined in any one of claims I3 23 7-353 or 47-51.
63. A moiety-linker conjugate as claimed in claim 62, wherein the moiety is as defined in any one of claims 28-35 or 47-51.
64. A first moiety-linker-second moiety conjugate wherein the linker is one of formulae I3 H3 IH3 IV3 V3 VI3 VII3 VIII3 IX or X as defined in any one of claims I3 23 7-353 or 47-5I3 and wherein the first and/or second moiety is as defined in any one of claims 28-35 or 47-51.
65. A conjugate as defined in any one of claims l-353 47-5I3 58 and 61-64 for use as a medicament.
66. A conjugate as defined in any one of claims l-353 47-51, 58 and 61-64 for use in a diagnostic method practised on the human or animal body.
67. Use of a conjugate as defined in any one of claims l-353 47-51, 58 and 61-64 in an ex vivo diagnostic method.
68. Use of a conjugate as defined in any one of claims 1-35, 47-51, 58 and 61-64 in the manufacture of a diagnostic tool for use in a diagnostic method practised on the human or animal body.
69. Use of a conjugate as defined in any one of claims 1-35, 47-51, 58 and 61-64 in the manufacture of a medicament for use in a method of treatment of the human or animal body.
70. A method of treating a patient comprising administering to that patient a conjugate as defined in any one of claims 1-35, 47-51, 58 and 61-64.
71. A method of diagnosing a condition in a patient comprising administering to that patient a conjugate as defined in any one of claims 1-35, 47-5I3 58 and 61-64.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0609370.2 | 2006-05-11 | ||
GBGB0609370.2A GB0609370D0 (en) | 2006-05-11 | 2006-05-11 | Process for cross-linking macromolecules |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007132207A2 true WO2007132207A2 (en) | 2007-11-22 |
WO2007132207A3 WO2007132207A3 (en) | 2008-08-21 |
Family
ID=36637328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/001745 WO2007132207A2 (en) | 2006-05-11 | 2007-05-11 | Process for cross-linking moieties |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB0609370D0 (en) |
WO (1) | WO2007132207A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018046741A1 (en) * | 2016-09-12 | 2018-03-15 | Gfc Diagnostics Ltd. | Method for detecting bacteria |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0398024A1 (en) * | 1989-04-19 | 1990-11-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Conjugates for tumor localization and/or tumortherapy |
EP0584794A2 (en) * | 1992-08-25 | 1994-03-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Electrobiochemical analytical method and electrodes |
US5532129A (en) * | 1991-11-07 | 1996-07-02 | Enterprise Partners Ii, L.P. | Self-organizing molecular photonic structures based on chromophore- and fluorophore-containing polynucleotides and methods of their use |
US6241863B1 (en) * | 1998-04-27 | 2001-06-05 | Harold G. Monbouquette | Amperometric biosensors based on redox enzymes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4007000B2 (en) * | 2001-12-25 | 2007-11-14 | 富士ゼロックス株式会社 | Conductive organic polymer |
-
2006
- 2006-05-11 GB GBGB0609370.2A patent/GB0609370D0/en not_active Ceased
-
2007
- 2007-05-11 GB GB0709127A patent/GB2438088B/en not_active Expired - Fee Related
- 2007-05-11 WO PCT/GB2007/001745 patent/WO2007132207A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0398024A1 (en) * | 1989-04-19 | 1990-11-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Conjugates for tumor localization and/or tumortherapy |
US5532129A (en) * | 1991-11-07 | 1996-07-02 | Enterprise Partners Ii, L.P. | Self-organizing molecular photonic structures based on chromophore- and fluorophore-containing polynucleotides and methods of their use |
EP0584794A2 (en) * | 1992-08-25 | 1994-03-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Electrobiochemical analytical method and electrodes |
US6241863B1 (en) * | 1998-04-27 | 2001-06-05 | Harold G. Monbouquette | Amperometric biosensors based on redox enzymes |
Non-Patent Citations (2)
Title |
---|
HUA S. ET AL.: "Lys515-Lys492 Cross-linking by DIDS Interferes with substrate Utilization by the Sarcoplasmic reticulum ATPase" BIOPHYSICAL JOURNAL, vol. 73, 1997, pages 2149-2155, XP007904540 * |
KAVANAUGH ET AL.: "Affinity labeling of hemoglobin with 4,4'-Diisothiocyanostilbene-2,2'-disulfona te: covalent cross-linking in the 2, 3-diphosphoglycerate binding site" BIOCHEMISTRY, vol. 27, 1988, pages 1804-1808, XP007904541 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018046741A1 (en) * | 2016-09-12 | 2018-03-15 | Gfc Diagnostics Ltd. | Method for detecting bacteria |
Also Published As
Publication number | Publication date |
---|---|
GB2438088A (en) | 2007-11-14 |
GB0609370D0 (en) | 2006-06-21 |
WO2007132207A3 (en) | 2008-08-21 |
GB2438088B (en) | 2010-04-28 |
GB0709127D0 (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3027770B2 (en) | Interference removers for use in immunoassays | |
US8389701B2 (en) | Multisignaling oligomeric or polymeric compositions comprising labeled moieties and binding partners | |
US6632929B1 (en) | Avidin derivatives and uses thereof | |
KR101104417B1 (en) | Method for specific covalent coupling of antibody using a photoactivable protein g variant | |
KR100920729B1 (en) | Method for preparing antibody monolayers which have controlled orientation using peptide hybrid | |
US5279955A (en) | Heterofunctional crosslinking agent for immobilizing reagents on plastic substrates | |
KR100252688B1 (en) | Interference - eliminating agent for application in immunoassays | |
EP2155792A1 (en) | Protein g-oligonucleotide conjugate | |
Stiller et al. | Fast and Efficient Fc-Specific Photoaffinity Labeling to Produce Antibody–DNA Conjugates | |
Nath et al. | On-bead antibody-small molecule conjugation using high-capacity magnetic beads | |
WO2007132207A2 (en) | Process for cross-linking moieties | |
KR100889587B1 (en) | Linker Molecules for Substrate Surface Treatment and Specific Protein Immobilization, and Method for Preparing the Same | |
JPH03255959A (en) | Polymer | |
US5384241A (en) | Specific binding assay compound with inhibitive self-quenching characteristics | |
JP7307793B2 (en) | Streptavidin-coated solid phase with binding pair members | |
JPH07121236B2 (en) | Enzyme controlled release system and organic complex reactant | |
JPS63246382A (en) | Biotinyl reagent and biotinylation using said reagent | |
FI60216C (en) | BIOLOGICALLY ACTIVE VID AFFINITETSREAKTIONER ANVAENDBART ADSORPTIONSMEDEL | |
WO2021254484A1 (en) | Efficient antibody dna-barcoding reagents for multiplexed molecular imaging | |
Suganuma et al. | Mirror-image Streptavidin with Specific Binding to “Non-natural” L-biotin | |
EP4234559A1 (en) | Serum resistant bis-sulfhydryl specific biotinylation reagent | |
KR20180090553A (en) | Liquid crystal microdroplets for sensing of antigen, biosensor using the same and sensing method of antigen using the same | |
JPH10104230A (en) | Method of detecting nucleic acid or the like, and labeled substance and detected substance | |
JP2024006375A (en) | Biotin labeling agent, biotin-labeled proteins, and immunoassay reagents containing biotin labeling agent | |
Bouillé et al. | Molecular analysis of the combining site of a monoclonal antibody against spermine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07732770 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07732770 Country of ref document: EP Kind code of ref document: A2 |